IR@PKUHSC  > 北京大学第一临床医学院  > 泌尿外科
其他题名Clinical study of diethylstilbestrol in hormone refractory prostate cancer
王建伟; 周利群; 纪世祺; 宋刚; 李学松; 何志嵩
关键词前列腺肿瘤 雌激素 己烯雌酚 Prostatic Neoplasms Estrogen Diethylstilbestrol
收录类别中国科技核心期刊 ; 中文核心期刊 ; CSCD
文章类型Journal Article
摘要目的 观察雌激素治疗激素难治性前列腺痛(HRPC)的临床效果及不良反应.方法 收集北京大学泌尿外科研究所32例激素难治性前列腺癌患者资料,治疗经过每天口服己烯雌酚2 mg,观察服药后血清前列腺特异抗原(PSA)变化,疾病进展时间,患者总体生存率、疾病特异生存率并观察药物毒副作用.结果 29例前列腺癌患者资料完整,平均用药时间(8.6±0.9)个月,PSA反应(PSA降低>50%)8例(27.5%),PSA稳定(PSA降低<50%,或PSA增高<25%)7例(24.1%);PSA进展(PSA增高>25%)14例(48.3%).总体中位疾病进展时间4个月(1~12个月).PSA反应患者中位疾病进展时间6个月(5~12个月).总体生存率为48.3%,疾病特异生存率为55.2%.主要不良反应为乳房胀痛硬结10例(34.5%);深静脉血栓3例(10.3%).结论 每天口服2 mg己烯雌酚治疗激素难治性前列腺癌可使27.5%的患者PSA降低>50%,24.1%患者PSA稳定,中位疾病进展时间4个月,雌激素治疗激素难治性前列腺癌效果肯定. Objective To summarize the clinical outcome and adverse events of estrogen therapy for hormone refractory prostate cancer.Methods A total of 32 patients with hormone refractory prostate cancer received diethylstilbestrol (DES) 2 mg daily at our institute.The data of PSA (prostate-specific antigen)change, time to progression, overall survival rate, disease-specific survival rate and adverse events were collected and analyzed.Results The data of 29 patients were complete.The mean duration of DES dosing was 8.6 ±0.9 months.Among them, 8 (27.5% ) patients achieved a PSA response with a 50% decrement of PSA or more.Seven (24.1% ) patients had a stable level of PSA(50% < PSA < 125% ) while 14 of 29 (48.3% ) maintained a PSA progression with a 25% increment of PSA or more.The overall median time to progression was 4 ( 1 - 12) months.And the median time to progression was 6 (5 - 12) months in the PSA response group.The overall survival rate was 48.3% and disease-specific survival rate 55.2%.The main adverse events were gynecomastia ( 10/29, 34.5% ) and deep vein thrombosis ( 3/29, 10.3% ).Conclusion When used for the treatment of hormone refractory prostate cancer, dethylstilbestrol at a daily dose of 2 mg can achieve a PSA response in 27.5% patients and a PSA stability in 24.1% patients.And the median time to progression is 4 months.Estrogen is efficacious for the patients with hormone refractory prostate cancer.
Citation statistics
Recommended Citation
GB/T 7714
王建伟,周利群,纪世祺,等. 雌激素治疗激素难治性前列腺癌的疗效观察[J]. 中华医学杂志,2011,91(32):2247-2249.
APA 王建伟,周利群,纪世祺,宋刚,李学松,&何志嵩.(2011).雌激素治疗激素难治性前列腺癌的疗效观察.中华医学杂志,91(32),2247-2249.
MLA 王建伟,et al."雌激素治疗激素难治性前列腺癌的疗效观察".中华医学杂志 91.32(2011):2247-2249.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Usage statistics
Export to Endnote
谷歌学术Similar articles in
[王建伟]'s Articles
[周利群]'s Articles
[纪世祺]'s Articles
百度学术Similar articles in
[王建伟]'s Articles
[周利群]'s Articles
[纪世祺]'s Articles
必应学术Similar articles in
[王建伟]'s Articles
[周利群]'s Articles
[纪世祺]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.